0000899243-22-037482.txt : 20221202
0000899243-22-037482.hdr.sgml : 20221202
20221202175229
ACCESSION NUMBER: 0000899243-22-037482
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221201
FILED AS OF DATE: 20221202
DATE AS OF CHANGE: 20221202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cheng Andrew
CENTRAL INDEX KEY: 0001778307
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 221443205
MAIL ADDRESS:
STREET 1: 170 HARBOR WAY, 3RD FLOOR
STREET 2: C/O AKERO THERAPEUTICS, INC.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-01
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001778307
Cheng Andrew
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President & CEO
Common Stock
2022-12-01
4
M
0
10000
0.615
A
320148
D
Common Stock
2022-12-01
4
S
0
10000
46.07
D
310148
D
Stock Option (Right to Buy)
0.615
2022-12-01
4
M
0
10000
0.00
D
2028-10-17
Common Stock
10000
210868
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.79 to $46.62, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
The options are vested and currently exercisable.
/s/ Jonathan Young, Attorney-in-Fact
2022-12-02